Oakworth Capital’s Gilead Sciences GILD Stock Holding History

Oakworth Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$592K	Hold	4,689	–	–	0.03%	136
2026 Q1	$654K	Hold	4,689	–	–	0.03%	123
2025 Q4	$576K	Sell	4,689 -59	-1%	-$7.17K	0.03%	126
2025 Q3	$527K	Buy	4,748 +742	+19%	+$84.3K	0.03%	131
2025 Q2	$444K	Hold	4,006	–	–	0.03%	130
2025 Q1	$449K	Hold	4,006	–	–	0.03%	129
2024 Q4	$370K	Sell	4,006 -300	-7%	-$27K	0.03%	150
2024 Q3	$361K	Hold	4,306	–	–	0.03%	149
2024 Q2	$295K	Hold	4,306	–	–	0.02%	157
2024 Q1	$315K	Hold	4,306	–	–	0.02%	160
2023 Q4	$349K	Hold	4,306	–	–	0.03%	141
2023 Q3	$323K	Hold	4,306	–	–	0.03%	131
2023 Q2	$332K	Hold	4,306	–	–	0.03%	132
2023 Q1	$357K	Hold	4,306	–	–	0.03%	124
2022 Q4	$370K	Hold	4,306	–	–	0.04%	115
2022 Q3	$266K	Sell	4,306 -145	-3%	-$9.14K	0.03%	135
2022 Q2	$275K	Sell	4,451 -138	-3%	-$8.54K	0.03%	139
2022 Q1	$273K	Hold	4,589	–	–	0.02%	154
2021 Q4	$333K	Sell	4,589 -839	-15%	-$57.8K	0.03%	137
2021 Q3	$379K	Hold	5,428	–	–	0.04%	122
2021 Q2	$374K	Sell	5,428 -1,200	-18%	-$80.1K	0.04%	129
2021 Q1	$428K	Sell	6,628 -1,523	-19%	-$98.2K	0.05%	112
2020 Q4	$475K	Hold	8,151	–	–	0.06%	97
2020 Q3	$515K	Sell	8,151 -1,581	-16%	-$110K	0.08%	82
2020 Q2	$749K	Buy	9,732 +150	+2%	+$11.5K	0.13%	62
2020 Q1	$716K	Buy	9,582 +1,608	+20%	+$111K	0.17%	55
2019 Q4	$525K	Sell	7,974 -106	-1%	-$6.9K	0.09%	82
2019 Q3	$512K	Hold	8,080	–	–	0.1%	77
2019 Q2	$546K	Buy	8,080 +142	+2%	+$9.34K	0.1%	85
2019 Q1	$516K	Sell	7,938 -2,560	-24%	-$170K	0.11%	85
2018 Q4	$657K	Buy	10,498 +2,137	+26%	+$149K	0.15%	64
2018 Q3	$645K	Sell	8,361 -840	-9%	-$63.4K	0.13%	72
2018 Q2	$652K	Buy	9,201 +1,891	+26%	+$134K	0.14%	63
2018 Q1	$528K	Hold	7,310	–	–	0.13%	74
2017 Q4	$547K	Sell	7,310 -318	-4%	-$24.1K	0.13%	78
2017 Q3	$638K	Sell	7,628 -60	-0.8%	-$4.59K	0.16%	68
2017 Q2	$544K	Sell	7,688 -2,302	-23%	-$153K	0.15%	74
2017 Q1	$678K	Sell	9,990 -254	-2%	-$17.9K	0.2%	59
2016 Q4	$755K	Sell	10,244 -185	-2%	-$13.8K	0.25%	50
2016 Q3	$825K	Hold	10,429	–	–	0.29%	45
2016 Q2	$908K	Hold	10,429	–	–	0.34%	47
2016 Q1	$958K	Hold	10,429	–	–	0.38%	43
2015 Q4	$1.05M	Buy	10,429 +334	+3%	+$34.8K	0.44%	36
2015 Q3	$991K	Hold	10,095	–	–	0.52%	24
2015 Q2	$1.19M	Hold	10,095	–	–	0.56%	24
2015 Q1	$1.01M	Hold	10,095	–	–	0.47%	32
2014 Q4	$951K	Buy	10,095 +3,000	+42%	+$310K	0.49%	33
2014 Q3	$763K	Hold	7,095	–	–	0.45%	28
2014 Q2	$588K	Hold	7,095	–	–	0.36%	33
2014 Q1	$503K	Hold	7,095	–	–	0.33%	39
2013 Q4	$533K	Buy	+7,095	New	+$494K	0.38%	28

Other funds holding GILD

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Oakworth Capital's GILD Position: Q2 2026 in Review

Oakworth Capital held its Gilead Sciences (GILD) position steady in Q2 2026 at 4,689 shares worth $592K. The position accounts for 0.03% of the portfolio, ranked #136.

Oakworth Capital first reported a position in GILD in Q4 2013 and has held it in 51 quarters since. The position peaked at $1.19M in Q2 2015. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Oakworth Capital held 4,689 shares of Gilead Sciences worth $592K as of Q2 2026.
Oakworth Capital left its Gilead Sciences share count unchanged in Q2 2026.
Gilead Sciences made up 0.03% of Oakworth Capital's portfolio in Q2 2026, its #136 holding.
Oakworth Capital first reported a position in Gilead Sciences in Q4 2013 and has held it in 51 quarters since.
Oakworth Capital's Gilead Sciences position peaked at $1.19M in Q2 2015.
690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Oakworth Capital's 13F filing for Q2 2026, filed 22 Jul 2026.